Loading...

PODCAST

Pharmaceutical Executive

Pharmaceutical Executive Podcast

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.

science life sciences

All Episodes

2:54

Pharmaceutical Executive Daily: FDA Grants...

Pharmaceutical Executive ·

2026/07/17

In today's Pharmaceutical Executive Daily, FDA converts Fabhalta's accelerated approval to full approval for IgA nephropathy, a Pharmaceutical Executive commentary argues AI-driven patient support still can't replace human connection, and Jasper Therapeutics closes its acquisition of Kira Pharmaceuticals in a deal combining a three-asset immunology pipeline.

en-us

3:02

Pharmaceutical Executive Daily: FDA Approves Lipfendra

Pharmaceutical Executive ·

2026/07/16

In today's Pharmaceutical Executive Daily, FDA approves Merck's Lipfendra as the first oral PCSK9 inhibitor for high cholesterol, Eli Lilly agrees to acquire AtaiBeckley for up to $3.8 billion, and a Pharmaceutical Executive podcast explores how better questions, not just more data, define strong biopharma leadership.

en-us

7:15

Hiring and Fostering Top Talent

Pharmaceutical Executive ·

2026/07/16

Nuvation CEO David Hung discusses his leadership style, success stories for building camaraderie, and his inspiration for joining the pharma and biotech industry.

en-us

27:06

The Power of Better Questions: How Great Leaders...

Pharmaceutical Executive ·

2026/07/16

What separates exceptional life sciences leaders from merely capable ones? According to veteran biopharma executive Craig Tooman, it often comes down to one deceptively simple skill: asking the right questions.In this episode of Leading Edge with Ken Banta, Tooman reflects on the lessons from a career journey spanning clinical, operational, financial and capital market roles, including as the CEO of Silence Therapeutics, and shares how curiosity, disciplined thinking and openness to unexpected

en-us

3:02

Pharmaceutical Executive Daily: FDA Approves...

Pharmaceutical Executive ·

2026/07/15

In today's Pharmaceutical Executive Daily, Steer Bio discusses its regenerative cell therapy platform for cancer-related lymphedema, FDA approves Celcuity's Revtorpyk as the first pan-PI3K and mTORC1/2 inhibitor for advanced breast cancer, and Insilico Medicine enters a strategic alliance with Bora Pharmaceuticals worth up to $2.5 billion.

en-us

2:34

Pharmaceutical Executive Daily: FDA Approves...

Pharmaceutical Executive ·

2026/07/14

In today's Pharmaceutical Executive Daily, AstraZeneca acquires global rights to Dizal Pharmaceutical's lung cancer drug Zegfrovy in a deal worth up to $1.5 billion, FDA approves a subcutaneous formulation of Leqembi for early Alzheimer's disease, and a pharmacy executive weighs in on the education gap facing patients starting GLP-1 therapies.

en-us

2:48

Pharmaceutical Executive Daily: FDA Issues CRL to...

Pharmaceutical Executive ·

2026/07/13

In today's Pharmaceutical Executive Daily, a new industry analysis warns that direct-to-patient pharma platforms are scaling faster than the safety infrastructure needed to support them, FDA issues a complete response letter to Elevar Therapeutics over manufacturing deficiencies in its liver cancer combination therapy, and Insilico Medicine deepens its partnership with China Medical System Holdings in a new AI-powered drug discovery collaboration worth up to $177 million.

en-us

3:43

Pharmaceutical Executive Daily: FDA Approves...

Pharmaceutical Executive ·

2026/07/10

In today's Pharmaceutical Executive Daily, FDA quietly pauses its real-time public release of complete response letters, FDA approves Sanofi's Sarclisa Escena as the first anticancer treatment in the U.S. to be administered via an on-body injector, and AstraZeneca shares fall nearly 10 percent after its Phase III Cardio-TTRansform trial of Wainua in transthyretin-mediated amyloid cardiomyopathy fails to meet its primary endpoint.

en-us

4:03

Pharmaceutical Executive Daily: FDA Approves Ennumo

Pharmaceutical Executive ·

2026/07/09

In today's Pharmaceutical Executive Daily, FDA approves Ennumo, a pharma roundup covers Chemomab Therapeutics' merger with AI-enabled precision medicine company Scipher Medicine and Teva's global licensing agreement with Polpharma Biologics, and Alina Chesnokova of Cencora examines how the rise of cold chain-dependent specialty therapies is fundamentally changing how pharmaceutical manufacturers think about commercialization strategy and supply chain partnerships.

en-us

3:02

Pharmaceutical Executive Daily: AI as Reinvention

Pharmaceutical Executive ·

2026/07/08

en-us

35:01

“AI as Reinvention”: Transforming the Business of...

Pharmaceutical Executive ·

2026/07/08

In this episode of the Pharm Exec podcast, Emmanuel Frenehard, executive vice president and chief digital officer at Sanofi, shares how one of the world's largest pharma companies is moving artificial intelligence from proof-of-concept to enterprise scale by embedding AI throughout R&D, manufacturing, commercial operations, and the employee experience. Joining Mike Christel, group managing editor, MJH Life Sciences, Frenehard breaks down Sanofi's three-tiered AI strategy — snackable,

en-us

3:00

Pharmaceutical Executive Daily: The Changing Reality...

Pharmaceutical Executive ·

2026/07/07

en-us

3:27

Pharmaceutical Executive Daily: The Medicare GLP-1...

Pharmaceutical Executive ·

2026/07/01

In today's Pharmaceutical Executive Daily, AlzeCure Pharma announces a collaboration with QuantumCell ApS worth more than $2.2 billion for global rights to its Neurostore platform including Alzheimer's candidate ACD856, the Medicare GLP-1 Bridge launches today, giving eligible Medicare Part D beneficiaries access to Wegovy, Foundayo, and Zepbound for a $50 monthly copay through the end of 2027, and Pharmaceutical Executive speaks with Ryan Last of Troutman Pepper Locke on the limits of targeted

en-us

3:15

Pharmaceutical Executive Daily: FDA Names Seven...

Pharmaceutical Executive ·

2026/06/30

In today's Pharmaceutical Executive Daily, FDA selects seven companies for its new PreCheck Pilot Program, Kirsten Whipple examines how the concept of healthspan is emerging from academic obscurity into a powerful consumer driver reshaping pharma's role in aging, and Pharmaceutical Executive speaks with Jeff Talbot of Roseman University of Health Sciences on how Las Vegas is positioning itself as an emerging life sciences hub beyond its casino-driven reputation.

en-us

3:50

Pharmaceutical Executive Daily: Ipsen Enters Merger...

Pharmaceutical Executive ·

2026/06/29

In today's Pharmaceutical Executive Daily, a pharma M&A roundup covers Ipsen's up to $1.75 billion acquisition of Kartos Therapeutics and Zymeworks' $929 million acquisition of Theravance Biopharma, Krista Pinto of Eversana argues that fully staffed pharma field teams are still missing revenue targets because the traditional deployment model itself needs to evolve, and EMA's CHMP issues a positive opinion recommending approval of Eli Lilly's Jaypirca for chronic lymphocytic leukemia across all lines

en-us

3:20

Pharmaceutical Executive Daily: FDA Clears Trodelvy...

Pharmaceutical Executive ·

2026/06/25

en-us

3:15

Pharmaceutical Executive Daily: Eli Lilly and Abbisko...

Pharmaceutical Executive ·

2026/06/24

In today's Pharmaceutical Executive Daily, Eli Lilly and Abbisko Therapeutics announce a new strategic research collaboration in which Abbisko will leverage its early-stage drug discovery platform to advance targets selected by Lilly, building on a prior partnership between the two companies, Pharmaceutical Executive speaks with Kyle Smith, president and COO of Aprecia Pharmaceuticals, on how the company's 3D printing technology enables real-time quality monitoring and rapid iteration to accelerate

en-us

3:45

Pharmaceutical Executive Daily: FDA Pilot Targets...

Pharmaceutical Executive ·

2026/06/23

In today's Pharmaceutical Executive Daily, the FDA announces Operation TrialBlazer, a pilot program aimed at cutting early-stage clinical trial timelines by six to 12 months as the US looks to reclaim its footing in global clinical research, market access expert Manasi Salgaonkar explains why Class of Trade classification is becoming one of the hardest — and most consequential — problems in pharmaceutical commercial operations, and Pharmaceutical Executive speaks with Kyle Smith, president and COO

en-us

3:21

Pharmaceutical Executive Daily: AbbVie Acquires...

Pharmaceutical Executive ·

2026/06/22

In today's Pharmaceutical Executive Daily, AbbVie announces a $10.9 billion agreement to acquire Apogee Therapeutics, adding a suite of clinical-stage immunology assets to its portfolio, Insilico Medicine enters an AI-powered drug discovery collaboration with SK Biopharmaceuticals valued at up to $2.5 billion to advance neuroimmune treatments in the central nervous system, and Pharmaceutical Executive speaks with Kyle Smith, president and COO of Aprecia Pharmaceuticals, on the real-world benefits

en-us

3:58

Pharmaceutical Executive Daily: FDA Advisory...

Pharmaceutical Executive ·

2026/06/19

In today's Pharmaceutical Executive Daily, an FDA advisory committee votes unanimously in favor of the benefit-risk profile of Moderna's investigational mRNA-1010 seasonal influenza vaccine across both younger and older adult populations, a pharma funding roundup covers Kardigan's upsized $400 million IPO debut on Nasdaq and cAMPfield Therapeutics' $180 million Series A launch, and Pharmaceutical Executive speaks with Brian Hilberdink of Boehringer Ingelheim on redefining what success looks like in

en-us

461 results

Similar Podcasts

Science Weekly

The Guardian

La Science CQFD

France Culture

The Dirt: an eKonomics podKast

eKonomics

La Science, CQFD

France Culture

Travelers In The Night

Albert D. Grauer